Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Weighted Average) (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $46.4 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 61.06% year-over-year to $46.4 million; the TTM value through Sep 2025 reached $46.4 million, up 61.06%, while the annual FY2024 figure was $28476.0, 11.65% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $46.4 million in Q3 2025 per RANI's latest filing, up from $36.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $46.9 million in Q2 2021 and bottomed at $19534.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $22.6 million, with a median of $25.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 51.1% in 2022, then surged 61.06% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $19534.0 in 2021, then grew by 21.93% to $23817.0 in 2022, then grew by 7.09% to $25505.0 in 2023, then grew by 11.65% to $28476.0 in 2024, then surged by 162998.75% to $46.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $46.4 million in Q3 2025, $36.5 million in Q2 2025, and $33.4 million in Q1 2025.